NCT04825015

Hemodynamic Monitoring in Liver Transplant With VEnaRt Cardiac Output Versus Swan-Ganz Catheter (VERO Study)

Hemodynamic Monitoring in Liver Transplant With VEnaRt Cardiac Output Versus Swan-Ganz Catheter VERO Study

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 26 (actual)
• Sponsor: Azienda Sanitaria-Universitaria Integrata di Udine · Academic / Other
• Sex: All
• Age: 18 Years – 99 Years
• Healthy volunteers: Not accepted

Summary

The Swan-Ganz catheter is the gold standard to measure cardiac output during liver transplantation surgery. This is an invasive hemodynamic monitoring system. The VenArt Cardiac Output (Mespere LifeSciences, Waterloo, Canada) is a new, innovative and non-invasive device that permits hemodynamic monitoring. With a software based on Fick's principle it is able to calculate cardiac output, cardiac index and continuous cardiac output. The hypothesis of this study is to investigate the precision and accuracy of this method versus the standard of care during liver transplantation.

Conditions

• Cardiac Output, Low
• Liver Transplant; Complications

Interventions

Type	Name	Description
DEVICE	VEnaRt Cardiac Output	Every patient is monitored during liver transplantation with VEnaRt Cardiac Output versus Swan-Ganz Catheter

Timeline

• Start date: 2021-04-01
• Primary completion: 2022-12-15
• Completion: 2022-12-15
• First posted: 2021-04-01
• Last updated: 2023-08-25

Locations

1 site across 1 country: Italy

Regulatory

• FDA-regulated device study